OPTION AGREEMENT AND PLAN OF MERGER BY AND AMONG ALCON RESEARCH, LTD., ITHACA MERGER SUB, INC., AND IVANTIS, INC. DATED AS OF November 9, 2018Option Agreement and Plan of Merger • February 15th, 2022 • Alcon Inc • Ophthalmic goods • Delaware
This OPTION AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of November 9, 2018 (the “Execution Date”), by and among (i) Alcon Research, Ltd., a Delaware corporation (the “Parent”), (ii) Ithaca Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (the “Merger Sub”), (iii) Ivantis, Inc., a Delaware corporation (the “Company”), and (iv) following its nomination and appointment, and delivery by it of a joinder to this Agreement, in each case, in accordance with Section 10.1 of this Agreement, the Stockholder Representative (as defined herein).
Option Agreement and Plan of MergerOption Agreement and Plan of Merger • July 30th, 2002 • Sun Network Group Inc • Air transportation, scheduled • Florida
THIS OPTION AGREEMENT AND PLAN OF MERGER (this “Agreement) is entered into as of the 28th day of June 2002, by and between Sun Network Group, Inc (“Sun”), a Florida company and Live Media Enterprises, Inc (“Live”), a Nevada corporation and Howard Mauskopf (“Mauskopf”), and is made with respect to the following facts:
Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of MAY 5, 2023Option Agreement and Plan of Merger • August 7th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This Option Agreement and Plan of Merger (this “Option Agreement”) dated as of May 5, 2023, by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.
AMENDMENT NO. 1 TO OPTION AGREEMENT AND PLAN OF MERGEROption Agreement and Plan of Merger • February 15th, 2022 • Alcon Inc • Ophthalmic goods
THIS AMENDMENT NO. 1 TO OPTION AGREEMENT AND PLAN OF MERGER (this “Amendment”) is made and entered into as of December 16, 2019 (the “Amendment Date”) by and among (a) Alcon Research, LLC, a Delaware limited liability company which was formerly known as Alcon Research, Ltd., a Delaware corporation (the “Parent”), (b) Ithaca Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent (the “Merger Sub”), (c) Ivantis, Inc., a Delaware corporation (the “Company”), and (d) the Stockholder Representative.
Option Agreement and Plan of Merger BY AND among Fibrogen, Inc., Fortis therapeutics, Inc. and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as Sellers’ Representative Dated as of JUNE 6, 2024Option Agreement and Plan of Merger • August 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations
This First Amended and Restated Option Agreement and Plan of Merger (this “Option Agreement”) dated as of June 6, 2024 (the “Restatement Effective Date”) amends and restates that certain Option Agreement and Plan of Merger, effective as of May 5, 2023 (the “Original Effective Date” and such agreement, the “Original Agreement”), by and among FibroGen, Inc., a Delaware corporation (“FibroGen”), Fortis Therapeutics, Inc., a Delaware corporation (“Fortis”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the Sellers’ Representative.
